ImmunityBio (IBRX) Accumulated Expenses (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Accumulated Expenses data on file, last reported at $48.2 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $48.2 million, up 72.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.2 million (up 72.84% YoY), and the FY2025 annual result was $46.8 million, up 15.42% from the prior year.
• Accumulated Expenses advanced to $48.2 million in Q1 2026 per IBRX's latest filing, from $46.8 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $64.9 million in Q3 2023 and troughed at $27.9 million in Q1 2025.
• A 5-year average of $46.0 million and a median of $43.6 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2026: Accumulated Expenses tumbled 43.3% in 2024, then jumped 72.84% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $41.8 million in 2022, then increased by 2.11% to $42.7 million in 2023, then retreated by 4.98% to $40.6 million in 2024, then grew by 15.42% to $46.8 million in 2025, then climbed by 2.92% to $48.2 million in 2026.
• Business Quant data shows IBRX's Accumulated Expenses at $48.2 million in Q1 2026, $46.8 million in Q4 2025, and $43.6 million in Q3 2025.